Pinkmartini的个人主页 - 老虎社区

Pinkmartini

Pinkmartini

A solo and freestyle trader

IP属地：未知

156关注

3粉丝

0主题

0勋章

2021-10-20

Heard that this was old news by Politico, causing the dip of the shares.

Novavax plunged over 20% in premarket trading<blockquote>Novavax 在盘前交易中暴跌超过 20%</blockquote>

2021-07-02

Always read more details and find out the companies that you are buying before you stuck with all these stocks.

抱歉，原内容已删除

2021-07-09

👍 nice

Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>

2021-09-21

😭gloomy day

Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce 和其他投资者本周值得关注的股票</blockquote>

2021-09-14

$Novavax(NVAX)$Whether you like it or not,Covid19 is here to stay,vaccine is not a cure but to mitigate the risk of death.

2021-07-30

Hoping it will go higher😁

Exxon posts highest profit in more than a year<blockquote>埃克森美孚公布一年多来最高利润</blockquote>

2021-07-14

$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound

2021-06-26

Yes APPLE is definitely a better buy😉

抱歉，原内容已删除

2021-06-26

It is kinda high now to buy in ~

抱歉，原内容已删除

2021-10-25

👍

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3585729847029660","uuid":"3585729847029660","gmtCreate":1622795342156,"gmtModify":1634652902800,"name":"Pinkmartini","pinyin":"pinkmartini","introduction":"","introductionEn":"","signature":"A solo and freestyle trader","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":156,"tweetSize":31,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":875712367,"gmtCreate":1637686423087,"gmtModify":1637686423087,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875712367","repostId":"1113618972","repostType":2,"isVote":1,"tweetType":1,"viewCount":2760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844014029,"gmtCreate":1636377122334,"gmtModify":1636377123305,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844014029","repostId":"1137044759","repostType":4,"isVote":1,"tweetType":1,"viewCount":4418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856808141,"gmtCreate":1635166163293,"gmtModify":1635166163416,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856808141","repostId":"1137044759","repostType":4,"isVote":1,"tweetType":1,"viewCount":3112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856801556,"gmtCreate":1635166123276,"gmtModify":1635166123394,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856801556","repostId":"851921142","repostType":1,"repost":{"id":851921142,"gmtCreate":1634865151633,"gmtModify":1635053291354,"author":{"id":"3583318222987864","authorId":"3583318222987864","name":"TheMilkyWay","avatar":"https://static.tigerbbs.com/190d59bcbcc876e15543cbd430d8c1f2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583318222987864","authorIdStr":"3583318222987864"},"themes":[],"title":"","htmlText":"Here’s why the <a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Covid 19 pill WILLNOT make the <a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid 19 vaccine irrelevant.Novavax was saved from the brink of bankruptcy by successfully formulating a non-mRNA Covid 19 vaccine with high efficacy. Its stock price was running high for the most part of 2020 - 2021. That was until the news of the Merck Covid 19 pill made headlines&nbsp;in Sep/ Oct 2021.&nbsp;While public confidence in Novavax started to waver months earlier due to the pharmaceutical company’s repeated delays in filing for emergency use authorisation (EUA) from the U.S. Food &amp; Drug Administration (FDA) for its Covid 19 vaccine &amp; the company’s&nbsp;stock price went through some wild fluctuations, there was no plunge","listText":"Here’s why the <a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Covid 19 pill WILLNOT make the <a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid 19 vaccine irrelevant.Novavax was saved from the brink of bankruptcy by successfully formulating a non-mRNA Covid 19 vaccine with high efficacy. Its stock price was running high for the most part of 2020 - 2021. That was until the news of the Merck Covid 19 pill made headlines&nbsp;in Sep/ Oct 2021.&nbsp;While public confidence in Novavax started to waver months earlier due to the pharmaceutical company’s repeated delays in filing for emergency use authorisation (EUA) from the U.S. Food &amp; Drug Administration (FDA) for its Covid 19 vaccine &amp; the company’s&nbsp;stock price went through some wild fluctuations, there was no plunge","text":"Here’s why the $Merck(MRK)$Covid 19 pill WILLNOT make the $Novavax(NVAX)$Covid 19 vaccine irrelevant.Novavax was saved from the brink of bankruptcy by successfully formulating a non-mRNA Covid 19 vaccine with high efficacy. Its stock price was running high for the most part of 2020 - 2021. That was until the news of the Merck Covid 19 pill made headlines in Sep/ Oct 2021. While public confidence in Novavax started to waver months earlier due to the pharmaceutical company’s repeated delays in filing for emergency use authorisation (EUA) from the U.S. Food & Drug Administration (FDA) for its Covid 19 vaccine & the company’s stock price went through some wild fluctuations, there was no plunge","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851921142","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859408655,"gmtCreate":1634718204697,"gmtModify":1634718404868,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","listText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","text":"Heard that this was old news by Politico, causing the dip of the shares.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859408655","repostId":"1174375951","repostType":4,"repost":{"id":"1174375951","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohunote.com/m/news/1174375951?lang=zh_CN&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading<blockquote>Novavax 在盘前交易中暴跌超过 20%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>全球疫苗分销商一直指望美国公司在 2022 年底前向中低收入国家提供 20 多亿剂疫苗--这是结束 Covid-19 大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但据三位直接了解该公司问题的人士称，由名为 COVAX 的国际财团开展的活动由于生产滞后而被严重推迟，现在可能会缺少 10 亿剂以上的疫苗，因为一家主要供应商在证明自己能够生产出符合监管机构质量标准的疫苗方面面临重大障碍。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>其他三名熟悉马里兰州 Novavax 和拜登政府之间讨论的人士证实了这一延迟，这标志着在新的、更具传播性的变种出现后，为世界接种疫苗的努力遭遇了重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在 2020 年向 Novavax 投资了 16 亿美元，这是当时向疫苗制造商投入的最多的一笔，希望它能为世界提供另一种安全有效疫苗的选择，以帮助预防 Covid-19。但该公司一直遇到生产问题。据多位熟悉 Novavax 困难的人士称，该公司用于测试疫苗纯度的方法没有达到监管机构的标准，而且该公司也未能证明自己能够生产出始终如一的疫苗。所有人都不愿透露姓名，讨论敏感的公司谈话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士称，尽管 Novavax 最近在向美国证券交易委员会提交的季度文件中证明了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品和药物管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每批疫苗应至少达到90%。该公司一直在努力实现接近这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>一位直接了解情况的人士说。另一位熟悉该公司生产工艺的人士说，Novavax 最近的纯度水平徘徊在 70% 左右。低纯度水平增加了最终产品中污染物或不必要物质的机会，降低了疫苗的有效性，或者增加了患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX 最近将 2021 年目标从 20 亿剂下调至 14.25 亿剂，该公司已经估计，在为发展中国家接种疫苗的过程中，其面临多达 10 亿剂的供应短缺。如果 Novavax 步履蹒跚，到 2022 年，赤字可能会增加一倍，导致数亿人失去对 Covid-19 的免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX 继续面临充足供应的挑战.在这种情况下，Novavax 的制造挑战和延误造成了巨大的破坏性，”COVAX 主任克里希纳-乌达亚库马尔（Krishna Udayakumar）说。<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后了数亿剂计划剂量，仅运送了 10 月份 7 亿剂目标中的 3.71 亿剂。它现在还面临无法实现已经下调的 2021 年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在 Novavax 和其他制造商的障碍之间，“COVAX 不得不争先恐后地实时大幅修改其供应战略，”Udayakumar 说。他补充说，因此，全球卫生组织正在强调更多的捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax 投资者关系和企业事务高级副总裁西尔维娅-泰勒（Silvia Taylor）在一份声明中告诉 POLITICO，该公司的分析测试方法已经过 “验证”，但没有回答有关 FDA 是否已签署这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>“疫苗开发和监管提交过程非常复杂，往往需要数年时间才能达到现在的水平。我们将在美国和全球范围内履行所有承诺的剂量，”泰勒说。</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不确定该公司是否拥有持续生产高质量疫苗所需的资源——这是 Novavax 在此之前必须达到的基准。这些人士表示，Novavax 有可能解决其制造问题，并在 2022 年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>诺瓦瓦克斯公司（Novavax）以前从未生产过疫苗，它拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速生产的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，用昆虫细胞制造关键成分。虽然科学家们熟悉这个过程，包括感染细胞以产生刺突蛋白，但它很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>有关 Novavax 持续生产问题的披露正值全球只有 36% 的人接种疫苗之际，发展中国家的领导人继续向美国施压，要求其提供更多疫苗。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这两个国家约有 1% 的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax 只是最新一家在承诺成为发展中国家主要疫苗贡献者后遇到核心生产问题的疫苗制造商。4 月，强生公司停止了由合同制造商运营的巴尔的摩工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现 1500 万剂疫苗意外被另一种 Covid-19 疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产过程恢复缓慢，迄今为止，强生公司仅生产了最初承诺在年底前向 COVAX 提供的 2 亿支疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>“国际倡导组织 Health GAP 的执行董事 Asia Russell 说：”对这些制造商来说，过度承诺和交付不足是游戏的名称。“这就是全球应对措施的基础设施，这太可怕了”。</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生公司不同，Novavax 是疫苗领域的新手。它从未成功推出疫苗，并且在疫情之前一直在财务上陷入困境。在经历了一系列药物开发失败后，该公司于 2019 年出售了生产设施，这笔交易还包括裁员 100 名员工。当年 5 月，Novavax 的股价跌至每股 36 美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着 Covid-19 的出现，该公司的命运发生了变化。在疫情早期争相开发一系列候选疫苗的过程中，特朗普执政授予 Novavax 16 亿美元，以帮助其 Covid-19 疫苗的研发工作——这是当时授予任何 Covid-19 疫苗制造商的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>这份合同代表了对 Novavax 能力的重大信任票--在后期试验显示疫苗对病毒有 90% 的有效率后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普执政高级官员也一再警告该公司，在扩大疫苗生产规模方面可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们尤其担心，一旦疫苗投入批量生产，Novavax 将很难确保疫苗始终符合 FDA 的严格质量标准--这正是困扰该公司数月之久的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“一位知情人士说：”他们加快了进程。“这很难做到。他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax 发言人泰勒在一份声明中说，该公司已经采纳了监管机构的反馈意见，并 “在扩大商业生产流程方面取得了巨大进展”。她说，到今年年底，该公司仍有望每月生产 1.5 亿剂疫苗，并在美国和国际上提交监管文件之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近向投资者发表的演讲中也表达了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准开始分发剂量。在aSept期间。在 29 投资者活动上，首席商务官约翰-特里齐诺（John Trizzino）表示，公司已经 “解决 ”了问题，并即将提交最终的监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>“Novavax 研发总裁格雷戈里-格伦（Gregory Glenn）补充说：”我们现在真的在测试我们的批次疫苗。“我们认为这很快就会结束”。</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员并不那么有信心。这些人士说，Novavax 的生产问题被认为比今年早些时候导致强生疫苗在紧急工厂生产的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始寻求其他国家的监管批准，但美国仍然怀疑它是否已经解决了根本的疫苗纯度缺陷，知情人士表示，这些缺陷影响了其在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四位知情人士表示，美国官员现在不再指望该公司最早要到明年才能获得 FDA 对该疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“一位知情人士说：”在某种程度上，我认为疗效永远不会超过与其中杂质相关的风险。“我对我们的处境并不感到惊讶”。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading<blockquote>Novavax 在盘前交易中暴跌超过 20%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading<blockquote>Novavax 在盘前交易中暴跌超过 20%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-20 16:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>全球疫苗分销商一直指望美国公司在 2022 年底前向中低收入国家提供 20 多亿剂疫苗--这是结束 Covid-19 大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但据三位直接了解该公司问题的人士称，由名为 COVAX 的国际财团开展的活动由于生产滞后而被严重推迟，现在可能会缺少 10 亿剂以上的疫苗，因为一家主要供应商在证明自己能够生产出符合监管机构质量标准的疫苗方面面临重大障碍。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>其他三名熟悉马里兰州 Novavax 和拜登政府之间讨论的人士证实了这一延迟，这标志着在新的、更具传播性的变种出现后，为世界接种疫苗的努力遭遇了重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在 2020 年向 Novavax 投资了 16 亿美元，这是当时向疫苗制造商投入的最多的一笔，希望它能为世界提供另一种安全有效疫苗的选择，以帮助预防 Covid-19。但该公司一直遇到生产问题。据多位熟悉 Novavax 困难的人士称，该公司用于测试疫苗纯度的方法没有达到监管机构的标准，而且该公司也未能证明自己能够生产出始终如一的疫苗。所有人都不愿透露姓名，讨论敏感的公司谈话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士称，尽管 Novavax 最近在向美国证券交易委员会提交的季度文件中证明了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品和药物管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每批疫苗应至少达到90%。该公司一直在努力实现接近这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>一位直接了解情况的人士说。另一位熟悉该公司生产工艺的人士说，Novavax 最近的纯度水平徘徊在 70% 左右。低纯度水平增加了最终产品中污染物或不必要物质的机会，降低了疫苗的有效性，或者增加了患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX 最近将 2021 年目标从 20 亿剂下调至 14.25 亿剂，该公司已经估计，在为发展中国家接种疫苗的过程中，其面临多达 10 亿剂的供应短缺。如果 Novavax 步履蹒跚，到 2022 年，赤字可能会增加一倍，导致数亿人失去对 Covid-19 的免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX 继续面临充足供应的挑战.在这种情况下，Novavax 的制造挑战和延误造成了巨大的破坏性，”COVAX 主任克里希纳-乌达亚库马尔（Krishna Udayakumar）说。<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后了数亿剂计划剂量，仅运送了 10 月份 7 亿剂目标中的 3.71 亿剂。它现在还面临无法实现已经下调的 2021 年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在 Novavax 和其他制造商的障碍之间，“COVAX 不得不争先恐后地实时大幅修改其供应战略，”Udayakumar 说。他补充说，因此，全球卫生组织正在强调更多的捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax 投资者关系和企业事务高级副总裁西尔维娅-泰勒（Silvia Taylor）在一份声明中告诉 POLITICO，该公司的分析测试方法已经过 “验证”，但没有回答有关 FDA 是否已签署这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>“疫苗开发和监管提交过程非常复杂，往往需要数年时间才能达到现在的水平。我们将在美国和全球范围内履行所有承诺的剂量，”泰勒说。</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不确定该公司是否拥有持续生产高质量疫苗所需的资源——这是 Novavax 在此之前必须达到的基准。这些人士表示，Novavax 有可能解决其制造问题，并在 2022 年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>诺瓦瓦克斯公司（Novavax）以前从未生产过疫苗，它拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速生产的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，用昆虫细胞制造关键成分。虽然科学家们熟悉这个过程，包括感染细胞以产生刺突蛋白，但它很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>有关 Novavax 持续生产问题的披露正值全球只有 36% 的人接种疫苗之际，发展中国家的领导人继续向美国施压，要求其提供更多疫苗。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这两个国家约有 1% 的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax 只是最新一家在承诺成为发展中国家主要疫苗贡献者后遇到核心生产问题的疫苗制造商。4 月，强生公司停止了由合同制造商运营的巴尔的摩工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现 1500 万剂疫苗意外被另一种 Covid-19 疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产过程恢复缓慢，迄今为止，强生公司仅生产了最初承诺在年底前向 COVAX 提供的 2 亿支疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>“国际倡导组织 Health GAP 的执行董事 Asia Russell 说：”对这些制造商来说，过度承诺和交付不足是游戏的名称。“这就是全球应对措施的基础设施，这太可怕了”。</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生公司不同，Novavax 是疫苗领域的新手。它从未成功推出疫苗，并且在疫情之前一直在财务上陷入困境。在经历了一系列药物开发失败后，该公司于 2019 年出售了生产设施，这笔交易还包括裁员 100 名员工。当年 5 月，Novavax 的股价跌至每股 36 美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着 Covid-19 的出现，该公司的命运发生了变化。在疫情早期争相开发一系列候选疫苗的过程中，特朗普执政授予 Novavax 16 亿美元，以帮助其 Covid-19 疫苗的研发工作——这是当时授予任何 Covid-19 疫苗制造商的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>这份合同代表了对 Novavax 能力的重大信任票--在后期试验显示疫苗对病毒有 90% 的有效率后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普执政高级官员也一再警告该公司，在扩大疫苗生产规模方面可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们尤其担心，一旦疫苗投入批量生产，Novavax 将很难确保疫苗始终符合 FDA 的严格质量标准--这正是困扰该公司数月之久的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“一位知情人士说：”他们加快了进程。“这很难做到。他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax 发言人泰勒在一份声明中说，该公司已经采纳了监管机构的反馈意见，并 “在扩大商业生产流程方面取得了巨大进展”。她说，到今年年底，该公司仍有望每月生产 1.5 亿剂疫苗，并在美国和国际上提交监管文件之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近向投资者发表的演讲中也表达了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准开始分发剂量。在aSept期间。在 29 投资者活动上，首席商务官约翰-特里齐诺（John Trizzino）表示，公司已经 “解决 ”了问题，并即将提交最终的监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>“Novavax 研发总裁格雷戈里-格伦（Gregory Glenn）补充说：”我们现在真的在测试我们的批次疫苗。“我们认为这很快就会结束”。</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员并不那么有信心。这些人士说，Novavax 的生产问题被认为比今年早些时候导致强生疫苗在紧急工厂生产的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始寻求其他国家的监管批准，但美国仍然怀疑它是否已经解决了根本的疫苗纯度缺陷，知情人士表示，这些缺陷影响了其在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四位知情人士表示，美国官员现在不再指望该公司最早要到明年才能获得 FDA 对该疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“一位知情人士说：”在某种程度上，我认为疗效永远不会超过与其中杂质相关的风险。“我对我们的处境并不感到惊讶”。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":3398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":860844688,"gmtCreate":1632156617744,"gmtModify":1632802435367,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"😭gloomy day","listText":"😭gloomy day","text":"😭gloomy day","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860844688","repostId":"1194891884","repostType":4,"repost":{"id":"1194891884","kind":"news","pubTimestamp":1632091615,"share":"https://www.laohunote.com/m/news/1194891884?lang=zh_CN&edition=full","pubTime":"2021-09-20 06:46","market":"us","language":"en","title":"Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce 和其他投资者本周值得关注的股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194891884","media":"Barrons","summary":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also","content":"<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p><p><blockquote>本周的重头戏将是美联储 9 月份的政策会议。投资者还将关注多项企业财报发布、投资者日和最新经济数据。</blockquote></p><p> Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p><p><blockquote>Lennar 将于周一公布季度收益，随后 Adobe、AutoZone 和 FedEx 将于周二公布业绩。通用磨坊周三发布报告，耐克、埃森哲、好市多批发和达顿餐厅周四发布报告。本周的投资者日包括周二的百健、周三的惠好和周四的 Salesforce.com。</blockquote></p><p> The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p><p><blockquote>美联储货币政策委员会将于本周二和周三召开会议。央行不太可能改变其目标利率区间，但可能会更新其开始减少每月资产购买的计划。周三下午美联储主席杰罗姆-鲍威尔（Jerome Powell）的新闻发布会将受到密切关注。</blockquote></p><p> Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p><p><blockquote>本周公布的经济数据包括世界大型企业联合会周四公布的 8 月份领先经济指数。美国房地产市场还将发布多项最新消息，包括周一公布的全国房屋建筑商协会（National Association of Home Builders）9 月份住房市场指数、周二公布的人口普查局（Census Bureau）8 月份新住宅建设数据以及周三公布的全国房地产经纪人协会（National Association of Realtors）8 月份成屋销售数据。</blockquote></p><p> <b>Monday 9/20</b></p><p><blockquote><b>9/20星期一</b></blockquote></p><p> Lennar reports third-quarter fiscal-2021 results.</p><p><blockquote>Lennar 报告 2021 财年第三季度业绩。</blockquote></p><p> Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p><p><blockquote>默克公司在欧洲肿瘤医学学会 2021 年大会上展示了其癌症药物组合的数据。</blockquote></p><p> <b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p><p><blockquote><b>全国协会</b>Home Builders 发布 9 月份房地产市场指数。经济学家预测读数为 73，比 8 月份的数字低 2 个百分点，8 月份是一年多来的最低值。</blockquote></p><p> <b>Tuesday 9/21</b></p><p><blockquote><b>9月21日星期二</b></blockquote></p><p> Adobe, AutoZone, and FedEx release earnings.</p><p><blockquote>Adobe、AutoZone 和联邦快递发布财报。</blockquote></p><p> Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p><p><blockquote>百健举办投资者日活动，讨论其神经科学疗法管道。</blockquote></p><p> <b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p><p><blockquote><b>人口普查局</b>8月份新住宅建设报告。普遍估计，经季节性调整后的新屋开工年率为 155 万套，比 7 月份的水平高出 1%。新屋开工率低于今年 3 月达到的金融危机后峰值 172.5 万套。</blockquote></p><p> <b>Wednesday 9/22</b></p><p><blockquote><b>9月22日星期三</b></blockquote></p><p> <b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p><p><blockquote><b>联邦公开市场委员会宣布</b>其货币政策决定。美联储可能会将联邦基金利率维持在接近于零的水平不变，但可能会暗示将在今年晚些时候削减资产购买。</blockquote></p><p> General Mills reports first-quarter fiscal-2022 results.</p><p><blockquote>通用磨坊公布 2022 财年第一季度业绩。</blockquote></p><p> Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p><p><blockquote>波士顿科学、惠好和百胜中国控股公司举办 2021 年投资者日。</blockquote></p><p> <b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p><p><blockquote><b>日本银行</b>宣布货币政策决定。人们普遍预计日本央行将维持其关键短期利率在负0.1%不变，因为由于新冠肺炎德尔塔变异毒株，东京都和其他地区在9月底前仍处于紧急状态。</blockquote></p><p> <b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p><p><blockquote><b>全国协会</b>房地产经纪人报告8月份的现房销售情况。经季节性调整后，预计全年售出房屋57.8万套，比7月份的59.9万套下降3.5%。</blockquote></p><p> <b>Thursday 9/23</b></p><p><blockquote><b>9月23日星期四</b></blockquote></p><p> Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p><p><blockquote>埃森哲、好市多批发、达顿餐厅和耐克公司在评级举行会议，讨论他们的季度业绩。</blockquote></p><p> Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p><p><blockquote>Salesforce.com 举办 2021 年投资者日。首席执行官马克·贝尼奥夫和Slack首席执行官斯图尔特·巴特菲尔德将出席。Salesforce 今年夏天完成了对 Slack 的 280 亿美元收购。</blockquote></p><p> <b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p><p><blockquote><b>会议委员会</b>发布8月份领先经济指数。经济学家预测，继 7 月份上涨 0.9% 之后，环比上涨 0.5%。世界大型企业联合会目前预计 2021 年国内生产总值增长 6%，2022 年增长 4%。</blockquote></p><p> <b>Friday 9/24</b></p><p><blockquote><b>9月24日星期五</b></blockquote></p><p> Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p><p><blockquote>堪萨斯城南方公司召开特别股东大会，就与加拿大太平洋铁路公司的合并提案进行投票。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce 和其他投资者本周值得关注的股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce 和其他投资者本周值得关注的股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-09-20 06:46</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p><p><blockquote>本周的重头戏将是美联储 9 月份的政策会议。投资者还将关注多项企业财报发布、投资者日和最新经济数据。</blockquote></p><p> Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p><p><blockquote>Lennar 将于周一公布季度收益，随后 Adobe、AutoZone 和 FedEx 将于周二公布业绩。通用磨坊周三发布报告，耐克、埃森哲、好市多批发和达顿餐厅周四发布报告。本周的投资者日包括周二的百健、周三的惠好和周四的 Salesforce.com。</blockquote></p><p> The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p><p><blockquote>美联储货币政策委员会将于本周二和周三召开会议。央行不太可能改变其目标利率区间，但可能会更新其开始减少每月资产购买的计划。周三下午美联储主席杰罗姆-鲍威尔（Jerome Powell）的新闻发布会将受到密切关注。</blockquote></p><p> Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p><p><blockquote>本周公布的经济数据包括世界大型企业联合会周四公布的 8 月份领先经济指数。美国房地产市场还将发布多项最新消息，包括周一公布的全国房屋建筑商协会（National Association of Home Builders）9 月份住房市场指数、周二公布的人口普查局（Census Bureau）8 月份新住宅建设数据以及周三公布的全国房地产经纪人协会（National Association of Realtors）8 月份成屋销售数据。</blockquote></p><p> <b>Monday 9/20</b></p><p><blockquote><b>9/20星期一</b></blockquote></p><p> Lennar reports third-quarter fiscal-2021 results.</p><p><blockquote>Lennar 报告 2021 财年第三季度业绩。</blockquote></p><p> Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p><p><blockquote>默克公司在欧洲肿瘤医学学会 2021 年大会上展示了其癌症药物组合的数据。</blockquote></p><p> <b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p><p><blockquote><b>全国协会</b>Home Builders 发布 9 月份房地产市场指数。经济学家预测读数为 73，比 8 月份的数字低 2 个百分点，8 月份是一年多来的最低值。</blockquote></p><p> <b>Tuesday 9/21</b></p><p><blockquote><b>9月21日星期二</b></blockquote></p><p> Adobe, AutoZone, and FedEx release earnings.</p><p><blockquote>Adobe、AutoZone 和联邦快递发布财报。</blockquote></p><p> Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p><p><blockquote>百健举办投资者日活动，讨论其神经科学疗法管道。</blockquote></p><p> <b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p><p><blockquote><b>人口普查局</b>8月份新住宅建设报告。普遍估计，经季节性调整后的新屋开工年率为 155 万套，比 7 月份的水平高出 1%。新屋开工率低于今年 3 月达到的金融危机后峰值 172.5 万套。</blockquote></p><p> <b>Wednesday 9/22</b></p><p><blockquote><b>9月22日星期三</b></blockquote></p><p> <b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p><p><blockquote><b>联邦公开市场委员会宣布</b>其货币政策决定。美联储可能会将联邦基金利率维持在接近于零的水平不变，但可能会暗示将在今年晚些时候削减资产购买。</blockquote></p><p> General Mills reports first-quarter fiscal-2022 results.</p><p><blockquote>通用磨坊公布 2022 财年第一季度业绩。</blockquote></p><p> Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p><p><blockquote>波士顿科学、惠好和百胜中国控股公司举办 2021 年投资者日。</blockquote></p><p> <b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p><p><blockquote><b>日本银行</b>宣布货币政策决定。人们普遍预计日本央行将维持其关键短期利率在负0.1%不变，因为由于新冠肺炎德尔塔变异毒株，东京都和其他地区在9月底前仍处于紧急状态。</blockquote></p><p> <b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p><p><blockquote><b>全国协会</b>房地产经纪人报告8月份的现房销售情况。经季节性调整后，预计全年售出房屋57.8万套，比7月份的59.9万套下降3.5%。</blockquote></p><p> <b>Thursday 9/23</b></p><p><blockquote><b>9月23日星期四</b></blockquote></p><p> Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p><p><blockquote>埃森哲、好市多批发、达顿餐厅和耐克公司在评级举行会议，讨论他们的季度业绩。</blockquote></p><p> Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p><p><blockquote>Salesforce.com 举办 2021 年投资者日。首席执行官马克·贝尼奥夫和Slack首席执行官斯图尔特·巴特菲尔德将出席。Salesforce 今年夏天完成了对 Slack 的 280 亿美元收购。</blockquote></p><p> <b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p><p><blockquote><b>会议委员会</b>发布8月份领先经济指数。经济学家预测，继 7 月份上涨 0.9% 之后，环比上涨 0.5%。世界大型企业联合会目前预计 2021 年国内生产总值增长 6%，2022 年增长 4%。</blockquote></p><p> <b>Friday 9/24</b></p><p><blockquote><b>9月24日星期五</b></blockquote></p><p> Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p><p><blockquote>堪萨斯城南方公司召开特别股东大会，就与加拿大太平洋铁路公司的合并提案进行投票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","NKE":"耐克","FDX":"联邦快递",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","COST":"好市多","CRM":"赛富时","ADBE":"Adobe"},"source_url":"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194891884","content_text":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.\nLennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report on Thursday. Investor days this week include Biogen on Tuesday, Weyerhaeuser on Wednesday, and Salesforce.com on Thursday.\nThe Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s press conference with Fed chair Jerome Powell will be closely watched.\nEconomic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’ existing-home sales for August on Wednesday.\nMonday 9/20\nLennar reports third-quarter fiscal-2021 results.\nMerck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.\nThe National Association of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.\nTuesday 9/21\nAdobe, AutoZone, and FedEx release earnings.\nBiogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.\nThe Census Bureau reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.\nWednesday 9/22\nThe FOMC announces its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.\nGeneral Mills reports first-quarter fiscal-2022 results.\nBoston Scientific,Weyerhaeuser, and Yum China Holdings host their 2021 investor days.\nTheBank of Japan announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.\nThe National Association of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5% from July’s 599,000.\nThursday 9/23\nAccenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.\nSalesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.\nThe Conference Board releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.\nFriday 9/24\nKansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.","news_type":1,"symbols_score_info":{"FDX":0.9,"COST":0.9,".SPX":0.9,"CRM":0.9,".DJI":0.9,"NKE":0.9,"ADBE":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":2292,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886401996,"gmtCreate":1631611320315,"gmtModify":1631884988513,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","text":"$Novavax(NVAX)$Whether you like it or not,Covid19 is here to stay,vaccine is not a cure but to mitigate the risk of death.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/886401996","isVote":1,"tweetType":1,"viewCount":2125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895481324,"gmtCreate":1628765708468,"gmtModify":1631888964471,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Impressive 😄","listText":"Impressive 😄","text":"Impressive 😄","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/895481324","repostId":"1176507211","repostType":2,"repost":{"id":"1176507211","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628755698,"share":"https://www.laohunote.com/m/news/1176507211?lang=zh_CN&edition=full","pubTime":"2021-08-12 16:08","market":"us","language":"en","title":"Clover Health shares rose nearly 12% in premarket trading.<blockquote>Clover Health 股价在盘前交易中上涨近 12%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176507211","media":"Tiger Newspress","summary":"Clover Health shares rose nearly 12% in premarket trading.\nHealth care technology company Clover Hea","content":"<p>Clover Health&nbsp;shares&nbsp;rose nearly&nbsp;12% in premarket&nbsp;trading.</p><p><blockquote>Clover Health 股价在盘前交易中上涨近 12%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/873c1d06cbd5a2c42b775f8b93fec480\" tg-width=\"910\" tg-height=\"651\" referrerpolicy=\"no-referrer\">Health care technology company&nbsp;<b>Clover Health</b>&nbsp;reported second-quarter earnings Wednesday afternoon.</p><p><blockquote>医疗保健技术公司<b>三叶草健康</b>周三下午公布了第二季度收益。</blockquote></p><p> Clover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.</p><p><blockquote>Clover Health 第二季度营收为 4.12 亿美元，同比增长 140%。本季度总收入超过了分析师预期的 2.054 亿美元。</blockquote></p><p> Clover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.</p><p><blockquote>Clover Health 预计整个财年的收入将在 14 亿至 15 亿美元之间。收入指引高于分析师 8.115 亿美元的预期。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health shares rose nearly 12% in premarket trading.<blockquote>Clover Health 股价在盘前交易中上涨近 12%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health shares rose nearly 12% in premarket trading.<blockquote>Clover Health 股价在盘前交易中上涨近 12%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-12 16:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Clover Health&nbsp;shares&nbsp;rose nearly&nbsp;12% in premarket&nbsp;trading.</p><p><blockquote>Clover Health 股价在盘前交易中上涨近 12%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/873c1d06cbd5a2c42b775f8b93fec480\" tg-width=\"910\" tg-height=\"651\" referrerpolicy=\"no-referrer\">Health care technology company&nbsp;<b>Clover Health</b>&nbsp;reported second-quarter earnings Wednesday afternoon.</p><p><blockquote>医疗保健技术公司<b>三叶草健康</b>周三下午公布了第二季度收益。</blockquote></p><p> Clover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.</p><p><blockquote>Clover Health 第二季度营收为 4.12 亿美元，同比增长 140%。本季度总收入超过了分析师预期的 2.054 亿美元。</blockquote></p><p> Clover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.</p><p><blockquote>Clover Health 预计整个财年的收入将在 14 亿至 15 亿美元之间。收入指引高于分析师 8.115 亿美元的预期。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176507211","content_text":"Clover Health shares rose nearly 12% in premarket trading.\nHealth care technology company Clover Health reported second-quarter earnings Wednesday afternoon.\nClover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.\nClover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.","news_type":1,"symbols_score_info":{"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":3448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807216642,"gmtCreate":1628038631786,"gmtModify":1631888964486,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807216642","repostId":"1128701390","repostType":4,"isVote":1,"tweetType":1,"viewCount":3105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806890941,"gmtCreate":1627646458283,"gmtModify":1631888964499,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Hoping it will go higher😁","listText":"Hoping it will go higher😁","text":"Hoping it will go higher😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806890941","repostId":"2155158989","repostType":2,"repost":{"id":"2155158989","kind":"highlight","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627644972,"share":"https://www.laohunote.com/m/news/2155158989?lang=zh_CN&edition=full","pubTime":"2021-07-30 19:36","market":"us","language":"en","title":"Exxon posts highest profit in more than a year<blockquote>埃克森美孚公布一年多来最高利润</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2155158989","media":"Tiger Newspress","summary":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its ","content":"<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p><p><blockquote>埃克森美孚周五公布了第一份季度业绩，此前董事会就其方向展开了一场有争议的斗争，由于石油、天然气和化学品需求反弹，埃克森美孚实现了一年多来的最大利润。</blockquote></p><p> Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>埃克森美孚股价在盘前交易中上涨近1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p><p><blockquote>石油生产商正在利用上季度原油价格翻倍的机会削减债务并增加股东派息，而不是增加支出来提高产量。</blockquote></p><p> Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p><p><blockquote>由于 COVID-19 大流行大幅削减需求，去年实施的大幅成本削减措施仍然有效，价格上涨推高了利润。</blockquote></p><p> Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p><p><blockquote>石油和天然气生产在本季度领先，营业利润为 31.9 亿美元。本季度产量下降 2%，至每天 360 万桶油当量。</blockquote></p><p> The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p><p><blockquote>该公司第二季度净利润为 46.9 亿美元，即每股 1.10 美元，而去年同期亏损 10.8 亿美元，即每股 26 美分，其中包括与扭转库存减记相关的收益。如果没有库存变化，损失将达到30亿美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exxon posts highest profit in more than a year<blockquote>埃克森美孚公布一年多来最高利润</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExxon posts highest profit in more than a year<blockquote>埃克森美孚公布一年多来最高利润</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-30 19:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p><p><blockquote>埃克森美孚周五公布了第一份季度业绩，此前董事会就其方向展开了一场有争议的斗争，由于石油、天然气和化学品需求反弹，埃克森美孚实现了一年多来的最大利润。</blockquote></p><p> Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>埃克森美孚股价在盘前交易中上涨近1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p><p><blockquote>石油生产商正在利用上季度原油价格翻倍的机会削减债务并增加股东派息，而不是增加支出来提高产量。</blockquote></p><p> Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p><p><blockquote>由于 COVID-19 大流行大幅削减需求，去年实施的大幅成本削减措施仍然有效，价格上涨推高了利润。</blockquote></p><p> Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p><p><blockquote>石油和天然气生产在本季度领先，营业利润为 31.9 亿美元。本季度产量下降 2%，至每天 360 万桶油当量。</blockquote></p><p> The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p><p><blockquote>该公司第二季度净利润为 46.9 亿美元，即每股 1.10 美元，而去年同期亏损 10.8 亿美元，即每股 26 美分，其中包括与扭转库存减记相关的收益。如果没有库存变化，损失将达到30亿美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155158989","content_text":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.\nExxon Mobil shares rose nearly 1% in premarket trading.\n\nOil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.\nDeep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.\nOil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.\nThe company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.","news_type":1,"symbols_score_info":{"XOM":0.9}},"isVote":1,"tweetType":1,"viewCount":2298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800206092,"gmtCreate":1627302702016,"gmtModify":1631888964510,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Yea it will go higher&nbsp;","listText":"Yea it will go higher&nbsp;","text":"Yea it will go higher","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800206092","repostId":"800203376","repostType":1,"repost":{"id":800203376,"gmtCreate":1627302521391,"gmtModify":1627313418331,"author":{"id":"3514329116425907","authorId":"3514329116425907","name":"小虎AV","avatar":"https://static.tigerbbs.com/162e12f8dcec770ec19f66f2abb0d5db","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3514329116425907","authorIdStr":"3514329116425907"},"themes":[],"title":"Apple stock hits record high: can it go higher?","htmlText":"\n \n \n  Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>\n \n","listText":"Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>","text":"Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.$Apple(AAPL)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800203376","isVote":1,"tweetType":2,"object":{"id":"bfaa109abbbf47f287e65d43086bc18d","tweetId":"800203376","videoUrl":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/cd0c38dc3701925921575081150/GALbAs4cmwYA.mp4","poster":"https://static.tigerbbs.com/10fac7242dd064ef2fda4f5c609ffb73"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178984102,"gmtCreate":1626781934506,"gmtModify":1631884320896,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Hope market rebound soon","listText":"Hope market rebound soon","text":"Hope market rebound soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178984102","repostId":"145269204","repostType":1,"repost":{"id":145269204,"gmtCreate":1626225863108,"gmtModify":1631885218880,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","listText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","text":"$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound","images":[{"img":"https://static.tigerbbs.com/348777b05f0b9f48562e326dd94278ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145269204","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":799,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145269204,"gmtCreate":1626225863108,"gmtModify":1631885218880,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","listText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","text":"$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound","images":[{"img":"https://static.tigerbbs.com/348777b05f0b9f48562e326dd94278ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/145269204","isVote":1,"tweetType":1,"viewCount":1233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":141185907,"gmtCreate":1625842118809,"gmtModify":1631888964523,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"👍 nice","listText":"👍 nice","text":"👍 nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/141185907","repostId":"1113783042","repostType":4,"repost":{"id":"1113783042","kind":"news","pubTimestamp":1625841673,"share":"https://www.laohunote.com/m/news/1113783042?lang=zh_CN&edition=full","pubTime":"2021-07-09 22:41","market":"sh","language":"en","title":"Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113783042","media":"Reuters","summary":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium","content":"<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p><p><blockquote>（路透社） - 中国电池制造商亿纬锂能周五表示，将入股一家小型锂生产商，并成立一家合资企业，建设一个耗资高达 18 亿元人民币（2.778 亿美元）的锂化学品项目。</blockquote></p><p> The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p><p><blockquote>此举是夏娃为确保电动汽车电池所用成分（例如锂）而采取的最新举措。此前，该公司持有钴生产商浙江华友钴业的少量股份，并与华友一起持有印度尼西亚价值 21 亿美元的镍钴项目 17% 的权益。</blockquote></p><p> EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p><p><blockquote>总部位于中国南方惠州的EVE在一份交易所文件中表示，计划收购金库伦锂业有限公司28.1%的股权，该公司在中国西北部以锂盐湖闻名的青海省生产金属锂。</blockquote></p><p> The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p><p><blockquote>EVE 表示，两家公司同意在青海成立一家合资企业，分别由金库仑持股 80% 和 20%，建设一家工厂，每年生产 3 万吨电池化学品碳酸锂和氢氧化锂。</blockquote></p><p> First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p><p><blockquote>它补充说，一期产量将为1万吨，项目总建设时间不超过36个月。</blockquote></p><p> EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p><p><blockquote>EVE表示，此次合资企业“有利于提高公司供应链的稳定性”，可以减少原材料价格波动带来的不利影响。</blockquote></p><p> Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p><p><blockquote>据亚洲金属评估，中国电池级碳酸锂价格在过去一个月下跌了约2%，但随着需求在三年低迷后反弹，2021年迄今为止仍上涨了65%以上。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-09 22:41</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p><p><blockquote>（路透社） - 中国电池制造商亿纬锂能周五表示，将入股一家小型锂生产商，并成立一家合资企业，建设一个耗资高达 18 亿元人民币（2.778 亿美元）的锂化学品项目。</blockquote></p><p> The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p><p><blockquote>此举是夏娃为确保电动汽车电池所用成分（例如锂）而采取的最新举措。此前，该公司持有钴生产商浙江华友钴业的少量股份，并与华友一起持有印度尼西亚价值 21 亿美元的镍钴项目 17% 的权益。</blockquote></p><p> EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p><p><blockquote>总部位于中国南方惠州的EVE在一份交易所文件中表示，计划收购金库伦锂业有限公司28.1%的股权，该公司在中国西北部以锂盐湖闻名的青海省生产金属锂。</blockquote></p><p> The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p><p><blockquote>EVE 表示，两家公司同意在青海成立一家合资企业，分别由金库仑持股 80% 和 20%，建设一家工厂，每年生产 3 万吨电池化学品碳酸锂和氢氧化锂。</blockquote></p><p> First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p><p><blockquote>它补充说，一期产量将为1万吨，项目总建设时间不超过36个月。</blockquote></p><p> EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p><p><blockquote>EVE表示，此次合资企业“有利于提高公司供应链的稳定性”，可以减少原材料价格波动带来的不利影响。</blockquote></p><p> Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p><p><blockquote>据亚洲金属评估，中国电池级碳酸锂价格在过去一个月下跌了约2%，但随着需求在三年低迷后反弹，2021年迄今为止仍上涨了65%以上。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"300014":"亿纬锂能"},"source_url":"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113783042","content_text":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).\nThe move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.\nEVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.\nThe two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.\nFirst-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.\nEVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.\nPrices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.","news_type":1,"symbols_score_info":{"300014":0.9}},"isVote":1,"tweetType":1,"viewCount":1215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140747649,"gmtCreate":1625677882381,"gmtModify":1631888964538,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Finally it soar again after a few months of low&nbsp;","listText":"Finally it soar again after a few months of low&nbsp;","text":"Finally it soar again after a few months of low","images":[{"img":"https://static.tigerbbs.com/2aba790188331bc227004cc234155500","width":"1125","height":"3633"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140747649","isVote":1,"tweetType":1,"viewCount":843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":140120190,"gmtCreate":1625638951210,"gmtModify":1631888964548,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"SDNL when is&nbsp;the next surge again? Any &nbsp; &nbsp; Feedback on this stocks&nbsp;","listText":"SDNL when is&nbsp;the next surge again? Any &nbsp; &nbsp; Feedback on this stocks&nbsp;","text":"SDNL when is the next surge again? Any Feedback on this stocks","images":[{"img":"https://static.tigerbbs.com/db83977a908c8cdd0e78c34cc5e64da7","width":"1125","height":"3828"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/140120190","isVote":1,"tweetType":1,"viewCount":915,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":156603367,"gmtCreate":1625215125259,"gmtModify":1631888964562,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"The future travel","listText":"The future travel","text":"The future travel","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156603367","repostId":"2148666820","repostType":4,"repost":{"id":"2148666820","kind":"highlight","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625212861,"share":"https://www.laohunote.com/m/news/2148666820?lang=zh_CN&edition=full","pubTime":"2021-07-02 16:01","market":"us","language":"en","title":"Branson aims to make space trip on July 11, ahead of Bezos<blockquote>布兰森计划于 7 月 11 日先于贝佐斯进行太空旅行</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2148666820","media":"Tiger Newspress","summary":"Virgin Galactic stock surged 37% in premarket trading.\n\nBillionaire entrepreneur Richard Branson wil","content":"<p>Virgin Galactic&nbsp;stock&nbsp;surged&nbsp;37%&nbsp;in premarket trading.</p><p><blockquote>维珍银河股价在盘前交易中飙升 37%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ec18b866bf2b11226994a81dad0c7a78\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Billionaire entrepreneur Richard Branson will travel to the edge of space on <a href=\"https://laohu8.com/S/SPCE.WS\">Virgin Galactic Holdings Inc</a>'s test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.</p><p><blockquote>亿万富翁企业家理查德·布兰森将前往太空边缘<a href=\"https://laohu8.com/S/SPCE.WS\">维珍银河控股公司</a>布兰森的太空旅游公司周四表示，7月11日的试飞击败了有志成为亿万富翁的宇航员杰夫·贝索斯。</blockquote></p><p> A successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.</p><p><blockquote>布兰森乘坐维珍VSS Unity太空飞机的成功飞行将标志着开启私人商业太空旅行新时代的竞赛中的一个关键里程碑。</blockquote></p><p> It would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.</p><p><blockquote>这也意味着布兰森将在竞争对手太空旅游企业蓝色起源的创始人贝佐斯之前穿越地球大气层。</blockquote></p><p> Bezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.</p><p><blockquote>零售巨头亚马逊公司的创始人贝佐斯定于 7 月 20 日与他的兄弟马克、开拓性女飞行员沃利·芬克以及一位迄今为止身份不明的人一起飞往太空，后者斥资 2800 万美元加入了亚轨道游乐设施。</blockquote></p><p> Reuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.</p><p><blockquote>路透社上个月报道称，布兰森正在考虑在贝佐斯计划旅行前几天执行一项引人注目的任务。</blockquote></p><p> The race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.</p><p><blockquote>这场竞赛还包括 SpaceX 首席执行官埃隆·马斯克 (Elon Musk)，其基础是乐观情绪，即随着新兴技术的验证和成本的下降，太空旅行将成为主流，从而推动瑞银估计到 2030 年每年可能达到 30 亿美元的旅游市场。马斯克尚未确定太空飞行的日期。</blockquote></p><p> \"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.</p><p><blockquote>布兰森在维珍宣布这一消息后发表的一份声明中表示：“维珍银河处于新商业航天工业的先锋，该工业将为人类开放太空并永远改变世界。”</blockquote></p><p> Branson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.</p><p><blockquote>维珍表示，布兰森 7 月 11 日的任务将是 VSS Unity 的第 22 次飞行测试，也是该公司的第四次载人航天飞行。</blockquote></p><p> But it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.</p><p><blockquote>但这将是第一次搭载两名飞行员和四名“任务专家”的完整机组人员，其中包括布兰森。</blockquote></p><p> Two additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.</p><p><blockquote>维珍表示，在维珍预计于 2022 年开始商业服务之前，计划再进行两次试飞。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson aims to make space trip on July 11, ahead of Bezos<blockquote>布兰森计划于 7 月 11 日先于贝佐斯进行太空旅行</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson aims to make space trip on July 11, ahead of Bezos<blockquote>布兰森计划于 7 月 11 日先于贝佐斯进行太空旅行</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-02 16:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Virgin Galactic&nbsp;stock&nbsp;surged&nbsp;37%&nbsp;in premarket trading.</p><p><blockquote>维珍银河股价在盘前交易中飙升 37%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ec18b866bf2b11226994a81dad0c7a78\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Billionaire entrepreneur Richard Branson will travel to the edge of space on <a href=\"https://laohu8.com/S/SPCE.WS\">Virgin Galactic Holdings Inc</a>'s test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.</p><p><blockquote>亿万富翁企业家理查德·布兰森将前往太空边缘<a href=\"https://laohu8.com/S/SPCE.WS\">维珍银河控股公司</a>布兰森的太空旅游公司周四表示，7月11日的试飞击败了有志成为亿万富翁的宇航员杰夫·贝索斯。</blockquote></p><p> A successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.</p><p><blockquote>布兰森乘坐维珍VSS Unity太空飞机的成功飞行将标志着开启私人商业太空旅行新时代的竞赛中的一个关键里程碑。</blockquote></p><p> It would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.</p><p><blockquote>这也意味着布兰森将在竞争对手太空旅游企业蓝色起源的创始人贝佐斯之前穿越地球大气层。</blockquote></p><p> Bezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.</p><p><blockquote>零售巨头亚马逊公司的创始人贝佐斯定于 7 月 20 日与他的兄弟马克、开拓性女飞行员沃利·芬克以及一位迄今为止身份不明的人一起飞往太空，后者斥资 2800 万美元加入了亚轨道游乐设施。</blockquote></p><p> Reuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.</p><p><blockquote>路透社上个月报道称，布兰森正在考虑在贝佐斯计划旅行前几天执行一项引人注目的任务。</blockquote></p><p> The race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.</p><p><blockquote>这场竞赛还包括 SpaceX 首席执行官埃隆·马斯克 (Elon Musk)，其基础是乐观情绪，即随着新兴技术的验证和成本的下降，太空旅行将成为主流，从而推动瑞银估计到 2030 年每年可能达到 30 亿美元的旅游市场。马斯克尚未确定太空飞行的日期。</blockquote></p><p> \"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.</p><p><blockquote>布兰森在维珍宣布这一消息后发表的一份声明中表示：“维珍银河处于新商业航天工业的先锋，该工业将为人类开放太空并永远改变世界。”</blockquote></p><p> Branson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.</p><p><blockquote>维珍表示，布兰森 7 月 11 日的任务将是 VSS Unity 的第 22 次飞行测试，也是该公司的第四次载人航天飞行。</blockquote></p><p> But it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.</p><p><blockquote>但这将是第一次搭载两名飞行员和四名“任务专家”的完整机组人员，其中包括布兰森。</blockquote></p><p> Two additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.</p><p><blockquote>维珍表示，在维珍预计于 2022 年开始商业服务之前，计划再进行两次试飞。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","QNETCN":"纳斯达克中美互联网老虎指数","09086":"华夏纳指-U","SPCE":"维珍银河","03086":"华夏纳指"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148666820","content_text":"Virgin Galactic stock surged 37% in premarket trading.\n\nBillionaire entrepreneur Richard Branson will travel to the edge of space on Virgin Galactic Holdings Inc's test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.\nA successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.\nIt would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.\nBezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.\nReuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.\nThe race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.\n\"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.\nBranson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.\nBut it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.\nTwo additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.","news_type":1,"symbols_score_info":{"SPCE":0.9,"03086":0.9,"09086":0.9,"QNETCN":0.9,"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":997,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156001375,"gmtCreate":1625184494997,"gmtModify":1631888964579,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","listText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","text":"Always read more details and find out the companies that you are buying before you stuck with all these stocks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156001375","repostId":"2148682246","repostType":4,"isVote":1,"tweetType":1,"viewCount":744,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151095720,"gmtCreate":1625056254660,"gmtModify":1631888964586,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Way to go","listText":"Way to go","text":"Way to go","images":[{"img":"https://static.tigerbbs.com/58f1cebd190596fc00c4e1e79a1da49d","width":"1125","height":"3558"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151095720","isVote":1,"tweetType":1,"viewCount":1014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":153084347,"gmtCreate":1624986192089,"gmtModify":1631891361228,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"I don’t think it would crash. Depending which angle you are looking at .&nbsp;","listText":"I don’t think it would crash. Depending which angle you are looking at .&nbsp;","text":"I don’t think it would crash. Depending which angle you are looking at .","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153084347","repostId":"2146388793","repostType":4,"isVote":1,"tweetType":1,"viewCount":753,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":859408655,"gmtCreate":1634718204697,"gmtModify":1634718404868,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","listText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","text":"Heard that this was old news by Politico, causing the dip of the shares.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859408655","repostId":"1174375951","repostType":4,"repost":{"id":"1174375951","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohunote.com/m/news/1174375951?lang=zh_CN&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading<blockquote>Novavax 在盘前交易中暴跌超过 20%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>全球疫苗分销商一直指望美国公司在 2022 年底前向中低收入国家提供 20 多亿剂疫苗--这是结束 Covid-19 大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但据三位直接了解该公司问题的人士称，由名为 COVAX 的国际财团开展的活动由于生产滞后而被严重推迟，现在可能会缺少 10 亿剂以上的疫苗，因为一家主要供应商在证明自己能够生产出符合监管机构质量标准的疫苗方面面临重大障碍。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>其他三名熟悉马里兰州 Novavax 和拜登政府之间讨论的人士证实了这一延迟，这标志着在新的、更具传播性的变种出现后，为世界接种疫苗的努力遭遇了重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在 2020 年向 Novavax 投资了 16 亿美元，这是当时向疫苗制造商投入的最多的一笔，希望它能为世界提供另一种安全有效疫苗的选择，以帮助预防 Covid-19。但该公司一直遇到生产问题。据多位熟悉 Novavax 困难的人士称，该公司用于测试疫苗纯度的方法没有达到监管机构的标准，而且该公司也未能证明自己能够生产出始终如一的疫苗。所有人都不愿透露姓名，讨论敏感的公司谈话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士称，尽管 Novavax 最近在向美国证券交易委员会提交的季度文件中证明了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品和药物管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每批疫苗应至少达到90%。该公司一直在努力实现接近这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>一位直接了解情况的人士说。另一位熟悉该公司生产工艺的人士说，Novavax 最近的纯度水平徘徊在 70% 左右。低纯度水平增加了最终产品中污染物或不必要物质的机会，降低了疫苗的有效性，或者增加了患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX 最近将 2021 年目标从 20 亿剂下调至 14.25 亿剂，该公司已经估计，在为发展中国家接种疫苗的过程中，其面临多达 10 亿剂的供应短缺。如果 Novavax 步履蹒跚，到 2022 年，赤字可能会增加一倍，导致数亿人失去对 Covid-19 的免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX 继续面临充足供应的挑战.在这种情况下，Novavax 的制造挑战和延误造成了巨大的破坏性，”COVAX 主任克里希纳-乌达亚库马尔（Krishna Udayakumar）说。<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后了数亿剂计划剂量，仅运送了 10 月份 7 亿剂目标中的 3.71 亿剂。它现在还面临无法实现已经下调的 2021 年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在 Novavax 和其他制造商的障碍之间，“COVAX 不得不争先恐后地实时大幅修改其供应战略，”Udayakumar 说。他补充说，因此，全球卫生组织正在强调更多的捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax 投资者关系和企业事务高级副总裁西尔维娅-泰勒（Silvia Taylor）在一份声明中告诉 POLITICO，该公司的分析测试方法已经过 “验证”，但没有回答有关 FDA 是否已签署这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>“疫苗开发和监管提交过程非常复杂，往往需要数年时间才能达到现在的水平。我们将在美国和全球范围内履行所有承诺的剂量，”泰勒说。</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不确定该公司是否拥有持续生产高质量疫苗所需的资源——这是 Novavax 在此之前必须达到的基准。这些人士表示，Novavax 有可能解决其制造问题，并在 2022 年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>诺瓦瓦克斯公司（Novavax）以前从未生产过疫苗，它拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速生产的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，用昆虫细胞制造关键成分。虽然科学家们熟悉这个过程，包括感染细胞以产生刺突蛋白，但它很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>有关 Novavax 持续生产问题的披露正值全球只有 36% 的人接种疫苗之际，发展中国家的领导人继续向美国施压，要求其提供更多疫苗。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这两个国家约有 1% 的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax 只是最新一家在承诺成为发展中国家主要疫苗贡献者后遇到核心生产问题的疫苗制造商。4 月，强生公司停止了由合同制造商运营的巴尔的摩工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现 1500 万剂疫苗意外被另一种 Covid-19 疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产过程恢复缓慢，迄今为止，强生公司仅生产了最初承诺在年底前向 COVAX 提供的 2 亿支疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>“国际倡导组织 Health GAP 的执行董事 Asia Russell 说：”对这些制造商来说，过度承诺和交付不足是游戏的名称。“这就是全球应对措施的基础设施，这太可怕了”。</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生公司不同，Novavax 是疫苗领域的新手。它从未成功推出疫苗，并且在疫情之前一直在财务上陷入困境。在经历了一系列药物开发失败后，该公司于 2019 年出售了生产设施，这笔交易还包括裁员 100 名员工。当年 5 月，Novavax 的股价跌至每股 36 美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着 Covid-19 的出现，该公司的命运发生了变化。在疫情早期争相开发一系列候选疫苗的过程中，特朗普执政授予 Novavax 16 亿美元，以帮助其 Covid-19 疫苗的研发工作——这是当时授予任何 Covid-19 疫苗制造商的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>这份合同代表了对 Novavax 能力的重大信任票--在后期试验显示疫苗对病毒有 90% 的有效率后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普执政高级官员也一再警告该公司，在扩大疫苗生产规模方面可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们尤其担心，一旦疫苗投入批量生产，Novavax 将很难确保疫苗始终符合 FDA 的严格质量标准--这正是困扰该公司数月之久的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“一位知情人士说：”他们加快了进程。“这很难做到。他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax 发言人泰勒在一份声明中说，该公司已经采纳了监管机构的反馈意见，并 “在扩大商业生产流程方面取得了巨大进展”。她说，到今年年底，该公司仍有望每月生产 1.5 亿剂疫苗，并在美国和国际上提交监管文件之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近向投资者发表的演讲中也表达了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准开始分发剂量。在aSept期间。在 29 投资者活动上，首席商务官约翰-特里齐诺（John Trizzino）表示，公司已经 “解决 ”了问题，并即将提交最终的监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>“Novavax 研发总裁格雷戈里-格伦（Gregory Glenn）补充说：”我们现在真的在测试我们的批次疫苗。“我们认为这很快就会结束”。</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员并不那么有信心。这些人士说，Novavax 的生产问题被认为比今年早些时候导致强生疫苗在紧急工厂生产的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始寻求其他国家的监管批准，但美国仍然怀疑它是否已经解决了根本的疫苗纯度缺陷，知情人士表示，这些缺陷影响了其在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四位知情人士表示，美国官员现在不再指望该公司最早要到明年才能获得 FDA 对该疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“一位知情人士说：”在某种程度上，我认为疗效永远不会超过与其中杂质相关的风险。“我对我们的处境并不感到惊讶”。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading<blockquote>Novavax 在盘前交易中暴跌超过 20%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading<blockquote>Novavax 在盘前交易中暴跌超过 20%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-20 16:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>全球疫苗分销商一直指望美国公司在 2022 年底前向中低收入国家提供 20 多亿剂疫苗--这是结束 Covid-19 大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但据三位直接了解该公司问题的人士称，由名为 COVAX 的国际财团开展的活动由于生产滞后而被严重推迟，现在可能会缺少 10 亿剂以上的疫苗，因为一家主要供应商在证明自己能够生产出符合监管机构质量标准的疫苗方面面临重大障碍。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>其他三名熟悉马里兰州 Novavax 和拜登政府之间讨论的人士证实了这一延迟，这标志着在新的、更具传播性的变种出现后，为世界接种疫苗的努力遭遇了重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在 2020 年向 Novavax 投资了 16 亿美元，这是当时向疫苗制造商投入的最多的一笔，希望它能为世界提供另一种安全有效疫苗的选择，以帮助预防 Covid-19。但该公司一直遇到生产问题。据多位熟悉 Novavax 困难的人士称，该公司用于测试疫苗纯度的方法没有达到监管机构的标准，而且该公司也未能证明自己能够生产出始终如一的疫苗。所有人都不愿透露姓名，讨论敏感的公司谈话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士称，尽管 Novavax 最近在向美国证券交易委员会提交的季度文件中证明了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品和药物管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每批疫苗应至少达到90%。该公司一直在努力实现接近这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>一位直接了解情况的人士说。另一位熟悉该公司生产工艺的人士说，Novavax 最近的纯度水平徘徊在 70% 左右。低纯度水平增加了最终产品中污染物或不必要物质的机会，降低了疫苗的有效性，或者增加了患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX 最近将 2021 年目标从 20 亿剂下调至 14.25 亿剂，该公司已经估计，在为发展中国家接种疫苗的过程中，其面临多达 10 亿剂的供应短缺。如果 Novavax 步履蹒跚，到 2022 年，赤字可能会增加一倍，导致数亿人失去对 Covid-19 的免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX 继续面临充足供应的挑战.在这种情况下，Novavax 的制造挑战和延误造成了巨大的破坏性，”COVAX 主任克里希纳-乌达亚库马尔（Krishna Udayakumar）说。<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后了数亿剂计划剂量，仅运送了 10 月份 7 亿剂目标中的 3.71 亿剂。它现在还面临无法实现已经下调的 2021 年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在 Novavax 和其他制造商的障碍之间，“COVAX 不得不争先恐后地实时大幅修改其供应战略，”Udayakumar 说。他补充说，因此，全球卫生组织正在强调更多的捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax 投资者关系和企业事务高级副总裁西尔维娅-泰勒（Silvia Taylor）在一份声明中告诉 POLITICO，该公司的分析测试方法已经过 “验证”，但没有回答有关 FDA 是否已签署这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>“疫苗开发和监管提交过程非常复杂，往往需要数年时间才能达到现在的水平。我们将在美国和全球范围内履行所有承诺的剂量，”泰勒说。</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不确定该公司是否拥有持续生产高质量疫苗所需的资源——这是 Novavax 在此之前必须达到的基准。这些人士表示，Novavax 有可能解决其制造问题，并在 2022 年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>诺瓦瓦克斯公司（Novavax）以前从未生产过疫苗，它拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速生产的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，用昆虫细胞制造关键成分。虽然科学家们熟悉这个过程，包括感染细胞以产生刺突蛋白，但它很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>有关 Novavax 持续生产问题的披露正值全球只有 36% 的人接种疫苗之际，发展中国家的领导人继续向美国施压，要求其提供更多疫苗。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这两个国家约有 1% 的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax 只是最新一家在承诺成为发展中国家主要疫苗贡献者后遇到核心生产问题的疫苗制造商。4 月，强生公司停止了由合同制造商运营的巴尔的摩工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现 1500 万剂疫苗意外被另一种 Covid-19 疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产过程恢复缓慢，迄今为止，强生公司仅生产了最初承诺在年底前向 COVAX 提供的 2 亿支疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>“国际倡导组织 Health GAP 的执行董事 Asia Russell 说：”对这些制造商来说，过度承诺和交付不足是游戏的名称。“这就是全球应对措施的基础设施，这太可怕了”。</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生公司不同，Novavax 是疫苗领域的新手。它从未成功推出疫苗，并且在疫情之前一直在财务上陷入困境。在经历了一系列药物开发失败后，该公司于 2019 年出售了生产设施，这笔交易还包括裁员 100 名员工。当年 5 月，Novavax 的股价跌至每股 36 美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着 Covid-19 的出现，该公司的命运发生了变化。在疫情早期争相开发一系列候选疫苗的过程中，特朗普执政授予 Novavax 16 亿美元，以帮助其 Covid-19 疫苗的研发工作——这是当时授予任何 Covid-19 疫苗制造商的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>这份合同代表了对 Novavax 能力的重大信任票--在后期试验显示疫苗对病毒有 90% 的有效率后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普执政高级官员也一再警告该公司，在扩大疫苗生产规模方面可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们尤其担心，一旦疫苗投入批量生产，Novavax 将很难确保疫苗始终符合 FDA 的严格质量标准--这正是困扰该公司数月之久的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“一位知情人士说：”他们加快了进程。“这很难做到。他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax 发言人泰勒在一份声明中说，该公司已经采纳了监管机构的反馈意见，并 “在扩大商业生产流程方面取得了巨大进展”。她说，到今年年底，该公司仍有望每月生产 1.5 亿剂疫苗，并在美国和国际上提交监管文件之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近向投资者发表的演讲中也表达了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准开始分发剂量。在aSept期间。在 29 投资者活动上，首席商务官约翰-特里齐诺（John Trizzino）表示，公司已经 “解决 ”了问题，并即将提交最终的监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>“Novavax 研发总裁格雷戈里-格伦（Gregory Glenn）补充说：”我们现在真的在测试我们的批次疫苗。“我们认为这很快就会结束”。</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员并不那么有信心。这些人士说，Novavax 的生产问题被认为比今年早些时候导致强生疫苗在紧急工厂生产的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始寻求其他国家的监管批准，但美国仍然怀疑它是否已经解决了根本的疫苗纯度缺陷，知情人士表示，这些缺陷影响了其在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四位知情人士表示，美国官员现在不再指望该公司最早要到明年才能获得 FDA 对该疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“一位知情人士说：”在某种程度上，我认为疗效永远不会超过与其中杂质相关的风险。“我对我们的处境并不感到惊讶”。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":3398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":156001375,"gmtCreate":1625184494997,"gmtModify":1631888964579,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","listText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","text":"Always read more details and find out the companies that you are buying before you stuck with all these stocks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156001375","repostId":"2148682246","repostType":4,"isVote":1,"tweetType":1,"viewCount":744,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141185907,"gmtCreate":1625842118809,"gmtModify":1631888964523,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"👍 nice","listText":"👍 nice","text":"👍 nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/141185907","repostId":"1113783042","repostType":4,"repost":{"id":"1113783042","kind":"news","pubTimestamp":1625841673,"share":"https://www.laohunote.com/m/news/1113783042?lang=zh_CN&edition=full","pubTime":"2021-07-09 22:41","market":"sh","language":"en","title":"Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113783042","media":"Reuters","summary":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium","content":"<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p><p><blockquote>（路透社） - 中国电池制造商亿纬锂能周五表示，将入股一家小型锂生产商，并成立一家合资企业，建设一个耗资高达 18 亿元人民币（2.778 亿美元）的锂化学品项目。</blockquote></p><p> The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p><p><blockquote>此举是夏娃为确保电动汽车电池所用成分（例如锂）而采取的最新举措。此前，该公司持有钴生产商浙江华友钴业的少量股份，并与华友一起持有印度尼西亚价值 21 亿美元的镍钴项目 17% 的权益。</blockquote></p><p> EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p><p><blockquote>总部位于中国南方惠州的EVE在一份交易所文件中表示，计划收购金库伦锂业有限公司28.1%的股权，该公司在中国西北部以锂盐湖闻名的青海省生产金属锂。</blockquote></p><p> The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p><p><blockquote>EVE 表示，两家公司同意在青海成立一家合资企业，分别由金库仑持股 80% 和 20%，建设一家工厂，每年生产 3 万吨电池化学品碳酸锂和氢氧化锂。</blockquote></p><p> First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p><p><blockquote>它补充说，一期产量将为1万吨，项目总建设时间不超过36个月。</blockquote></p><p> EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p><p><blockquote>EVE表示，此次合资企业“有利于提高公司供应链的稳定性”，可以减少原材料价格波动带来的不利影响。</blockquote></p><p> Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p><p><blockquote>据亚洲金属评估，中国电池级碳酸锂价格在过去一个月下跌了约2%，但随着需求在三年低迷后反弹，2021年迄今为止仍上涨了65%以上。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-09 22:41</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p><p><blockquote>（路透社） - 中国电池制造商亿纬锂能周五表示，将入股一家小型锂生产商，并成立一家合资企业，建设一个耗资高达 18 亿元人民币（2.778 亿美元）的锂化学品项目。</blockquote></p><p> The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p><p><blockquote>此举是夏娃为确保电动汽车电池所用成分（例如锂）而采取的最新举措。此前，该公司持有钴生产商浙江华友钴业的少量股份，并与华友一起持有印度尼西亚价值 21 亿美元的镍钴项目 17% 的权益。</blockquote></p><p> EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p><p><blockquote>总部位于中国南方惠州的EVE在一份交易所文件中表示，计划收购金库伦锂业有限公司28.1%的股权，该公司在中国西北部以锂盐湖闻名的青海省生产金属锂。</blockquote></p><p> The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p><p><blockquote>EVE 表示，两家公司同意在青海成立一家合资企业，分别由金库仑持股 80% 和 20%，建设一家工厂，每年生产 3 万吨电池化学品碳酸锂和氢氧化锂。</blockquote></p><p> First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p><p><blockquote>它补充说，一期产量将为1万吨，项目总建设时间不超过36个月。</blockquote></p><p> EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p><p><blockquote>EVE表示，此次合资企业“有利于提高公司供应链的稳定性”，可以减少原材料价格波动带来的不利影响。</blockquote></p><p> Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p><p><blockquote>据亚洲金属评估，中国电池级碳酸锂价格在过去一个月下跌了约2%，但随着需求在三年低迷后反弹，2021年迄今为止仍上涨了65%以上。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"300014":"亿纬锂能"},"source_url":"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113783042","content_text":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).\nThe move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.\nEVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.\nThe two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.\nFirst-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.\nEVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.\nPrices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.","news_type":1,"symbols_score_info":{"300014":0.9}},"isVote":1,"tweetType":1,"viewCount":1215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860844688,"gmtCreate":1632156617744,"gmtModify":1632802435367,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"😭gloomy day","listText":"😭gloomy day","text":"😭gloomy day","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860844688","repostId":"1194891884","repostType":4,"repost":{"id":"1194891884","kind":"news","pubTimestamp":1632091615,"share":"https://www.laohunote.com/m/news/1194891884?lang=zh_CN&edition=full","pubTime":"2021-09-20 06:46","market":"us","language":"en","title":"Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce 和其他投资者本周值得关注的股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194891884","media":"Barrons","summary":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also","content":"<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p><p><blockquote>本周的重头戏将是美联储 9 月份的政策会议。投资者还将关注多项企业财报发布、投资者日和最新经济数据。</blockquote></p><p> Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p><p><blockquote>Lennar 将于周一公布季度收益，随后 Adobe、AutoZone 和 FedEx 将于周二公布业绩。通用磨坊周三发布报告，耐克、埃森哲、好市多批发和达顿餐厅周四发布报告。本周的投资者日包括周二的百健、周三的惠好和周四的 Salesforce.com。</blockquote></p><p> The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p><p><blockquote>美联储货币政策委员会将于本周二和周三召开会议。央行不太可能改变其目标利率区间，但可能会更新其开始减少每月资产购买的计划。周三下午美联储主席杰罗姆-鲍威尔（Jerome Powell）的新闻发布会将受到密切关注。</blockquote></p><p> Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p><p><blockquote>本周公布的经济数据包括世界大型企业联合会周四公布的 8 月份领先经济指数。美国房地产市场还将发布多项最新消息，包括周一公布的全国房屋建筑商协会（National Association of Home Builders）9 月份住房市场指数、周二公布的人口普查局（Census Bureau）8 月份新住宅建设数据以及周三公布的全国房地产经纪人协会（National Association of Realtors）8 月份成屋销售数据。</blockquote></p><p> <b>Monday 9/20</b></p><p><blockquote><b>9/20星期一</b></blockquote></p><p> Lennar reports third-quarter fiscal-2021 results.</p><p><blockquote>Lennar 报告 2021 财年第三季度业绩。</blockquote></p><p> Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p><p><blockquote>默克公司在欧洲肿瘤医学学会 2021 年大会上展示了其癌症药物组合的数据。</blockquote></p><p> <b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p><p><blockquote><b>全国协会</b>Home Builders 发布 9 月份房地产市场指数。经济学家预测读数为 73，比 8 月份的数字低 2 个百分点，8 月份是一年多来的最低值。</blockquote></p><p> <b>Tuesday 9/21</b></p><p><blockquote><b>9月21日星期二</b></blockquote></p><p> Adobe, AutoZone, and FedEx release earnings.</p><p><blockquote>Adobe、AutoZone 和联邦快递发布财报。</blockquote></p><p> Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p><p><blockquote>百健举办投资者日活动，讨论其神经科学疗法管道。</blockquote></p><p> <b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p><p><blockquote><b>人口普查局</b>8月份新住宅建设报告。普遍估计，经季节性调整后的新屋开工年率为 155 万套，比 7 月份的水平高出 1%。新屋开工率低于今年 3 月达到的金融危机后峰值 172.5 万套。</blockquote></p><p> <b>Wednesday 9/22</b></p><p><blockquote><b>9月22日星期三</b></blockquote></p><p> <b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p><p><blockquote><b>联邦公开市场委员会宣布</b>其货币政策决定。美联储可能会将联邦基金利率维持在接近于零的水平不变，但可能会暗示将在今年晚些时候削减资产购买。</blockquote></p><p> General Mills reports first-quarter fiscal-2022 results.</p><p><blockquote>通用磨坊公布 2022 财年第一季度业绩。</blockquote></p><p> Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p><p><blockquote>波士顿科学、惠好和百胜中国控股公司举办 2021 年投资者日。</blockquote></p><p> <b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p><p><blockquote><b>日本银行</b>宣布货币政策决定。人们普遍预计日本央行将维持其关键短期利率在负0.1%不变，因为由于新冠肺炎德尔塔变异毒株，东京都和其他地区在9月底前仍处于紧急状态。</blockquote></p><p> <b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p><p><blockquote><b>全国协会</b>房地产经纪人报告8月份的现房销售情况。经季节性调整后，预计全年售出房屋57.8万套，比7月份的59.9万套下降3.5%。</blockquote></p><p> <b>Thursday 9/23</b></p><p><blockquote><b>9月23日星期四</b></blockquote></p><p> Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p><p><blockquote>埃森哲、好市多批发、达顿餐厅和耐克公司在评级举行会议，讨论他们的季度业绩。</blockquote></p><p> Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p><p><blockquote>Salesforce.com 举办 2021 年投资者日。首席执行官马克·贝尼奥夫和Slack首席执行官斯图尔特·巴特菲尔德将出席。Salesforce 今年夏天完成了对 Slack 的 280 亿美元收购。</blockquote></p><p> <b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p><p><blockquote><b>会议委员会</b>发布8月份领先经济指数。经济学家预测，继 7 月份上涨 0.9% 之后，环比上涨 0.5%。世界大型企业联合会目前预计 2021 年国内生产总值增长 6%，2022 年增长 4%。</blockquote></p><p> <b>Friday 9/24</b></p><p><blockquote><b>9月24日星期五</b></blockquote></p><p> Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p><p><blockquote>堪萨斯城南方公司召开特别股东大会，就与加拿大太平洋铁路公司的合并提案进行投票。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce 和其他投资者本周值得关注的股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce 和其他投资者本周值得关注的股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-09-20 06:46</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p><p><blockquote>本周的重头戏将是美联储 9 月份的政策会议。投资者还将关注多项企业财报发布、投资者日和最新经济数据。</blockquote></p><p> Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p><p><blockquote>Lennar 将于周一公布季度收益，随后 Adobe、AutoZone 和 FedEx 将于周二公布业绩。通用磨坊周三发布报告，耐克、埃森哲、好市多批发和达顿餐厅周四发布报告。本周的投资者日包括周二的百健、周三的惠好和周四的 Salesforce.com。</blockquote></p><p> The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p><p><blockquote>美联储货币政策委员会将于本周二和周三召开会议。央行不太可能改变其目标利率区间，但可能会更新其开始减少每月资产购买的计划。周三下午美联储主席杰罗姆-鲍威尔（Jerome Powell）的新闻发布会将受到密切关注。</blockquote></p><p> Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p><p><blockquote>本周公布的经济数据包括世界大型企业联合会周四公布的 8 月份领先经济指数。美国房地产市场还将发布多项最新消息，包括周一公布的全国房屋建筑商协会（National Association of Home Builders）9 月份住房市场指数、周二公布的人口普查局（Census Bureau）8 月份新住宅建设数据以及周三公布的全国房地产经纪人协会（National Association of Realtors）8 月份成屋销售数据。</blockquote></p><p> <b>Monday 9/20</b></p><p><blockquote><b>9/20星期一</b></blockquote></p><p> Lennar reports third-quarter fiscal-2021 results.</p><p><blockquote>Lennar 报告 2021 财年第三季度业绩。</blockquote></p><p> Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p><p><blockquote>默克公司在欧洲肿瘤医学学会 2021 年大会上展示了其癌症药物组合的数据。</blockquote></p><p> <b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p><p><blockquote><b>全国协会</b>Home Builders 发布 9 月份房地产市场指数。经济学家预测读数为 73，比 8 月份的数字低 2 个百分点，8 月份是一年多来的最低值。</blockquote></p><p> <b>Tuesday 9/21</b></p><p><blockquote><b>9月21日星期二</b></blockquote></p><p> Adobe, AutoZone, and FedEx release earnings.</p><p><blockquote>Adobe、AutoZone 和联邦快递发布财报。</blockquote></p><p> Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p><p><blockquote>百健举办投资者日活动，讨论其神经科学疗法管道。</blockquote></p><p> <b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p><p><blockquote><b>人口普查局</b>8月份新住宅建设报告。普遍估计，经季节性调整后的新屋开工年率为 155 万套，比 7 月份的水平高出 1%。新屋开工率低于今年 3 月达到的金融危机后峰值 172.5 万套。</blockquote></p><p> <b>Wednesday 9/22</b></p><p><blockquote><b>9月22日星期三</b></blockquote></p><p> <b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p><p><blockquote><b>联邦公开市场委员会宣布</b>其货币政策决定。美联储可能会将联邦基金利率维持在接近于零的水平不变，但可能会暗示将在今年晚些时候削减资产购买。</blockquote></p><p> General Mills reports first-quarter fiscal-2022 results.</p><p><blockquote>通用磨坊公布 2022 财年第一季度业绩。</blockquote></p><p> Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p><p><blockquote>波士顿科学、惠好和百胜中国控股公司举办 2021 年投资者日。</blockquote></p><p> <b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p><p><blockquote><b>日本银行</b>宣布货币政策决定。人们普遍预计日本央行将维持其关键短期利率在负0.1%不变，因为由于新冠肺炎德尔塔变异毒株，东京都和其他地区在9月底前仍处于紧急状态。</blockquote></p><p> <b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p><p><blockquote><b>全国协会</b>房地产经纪人报告8月份的现房销售情况。经季节性调整后，预计全年售出房屋57.8万套，比7月份的59.9万套下降3.5%。</blockquote></p><p> <b>Thursday 9/23</b></p><p><blockquote><b>9月23日星期四</b></blockquote></p><p> Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p><p><blockquote>埃森哲、好市多批发、达顿餐厅和耐克公司在评级举行会议，讨论他们的季度业绩。</blockquote></p><p> Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p><p><blockquote>Salesforce.com 举办 2021 年投资者日。首席执行官马克·贝尼奥夫和Slack首席执行官斯图尔特·巴特菲尔德将出席。Salesforce 今年夏天完成了对 Slack 的 280 亿美元收购。</blockquote></p><p> <b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p><p><blockquote><b>会议委员会</b>发布8月份领先经济指数。经济学家预测，继 7 月份上涨 0.9% 之后，环比上涨 0.5%。世界大型企业联合会目前预计 2021 年国内生产总值增长 6%，2022 年增长 4%。</blockquote></p><p> <b>Friday 9/24</b></p><p><blockquote><b>9月24日星期五</b></blockquote></p><p> Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p><p><blockquote>堪萨斯城南方公司召开特别股东大会，就与加拿大太平洋铁路公司的合并提案进行投票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","NKE":"耐克","FDX":"联邦快递",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","COST":"好市多","CRM":"赛富时","ADBE":"Adobe"},"source_url":"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194891884","content_text":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.\nLennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report on Thursday. Investor days this week include Biogen on Tuesday, Weyerhaeuser on Wednesday, and Salesforce.com on Thursday.\nThe Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s press conference with Fed chair Jerome Powell will be closely watched.\nEconomic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’ existing-home sales for August on Wednesday.\nMonday 9/20\nLennar reports third-quarter fiscal-2021 results.\nMerck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.\nThe National Association of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.\nTuesday 9/21\nAdobe, AutoZone, and FedEx release earnings.\nBiogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.\nThe Census Bureau reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.\nWednesday 9/22\nThe FOMC announces its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.\nGeneral Mills reports first-quarter fiscal-2022 results.\nBoston Scientific,Weyerhaeuser, and Yum China Holdings host their 2021 investor days.\nTheBank of Japan announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.\nThe National Association of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5% from July’s 599,000.\nThursday 9/23\nAccenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.\nSalesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.\nThe Conference Board releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.\nFriday 9/24\nKansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.","news_type":1,"symbols_score_info":{"FDX":0.9,"COST":0.9,".SPX":0.9,"CRM":0.9,".DJI":0.9,"NKE":0.9,"ADBE":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":2292,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886401996,"gmtCreate":1631611320315,"gmtModify":1631884988513,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","text":"$Novavax(NVAX)$Whether you like it or not,Covid19 is here to stay,vaccine is not a cure but to mitigate the risk of death.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/886401996","isVote":1,"tweetType":1,"viewCount":2125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806890941,"gmtCreate":1627646458283,"gmtModify":1631888964499,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Hoping it will go higher😁","listText":"Hoping it will go higher😁","text":"Hoping it will go higher😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806890941","repostId":"2155158989","repostType":2,"repost":{"id":"2155158989","kind":"highlight","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627644972,"share":"https://www.laohunote.com/m/news/2155158989?lang=zh_CN&edition=full","pubTime":"2021-07-30 19:36","market":"us","language":"en","title":"Exxon posts highest profit in more than a year<blockquote>埃克森美孚公布一年多来最高利润</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2155158989","media":"Tiger Newspress","summary":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its ","content":"<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p><p><blockquote>埃克森美孚周五公布了第一份季度业绩，此前董事会就其方向展开了一场有争议的斗争，由于石油、天然气和化学品需求反弹，埃克森美孚实现了一年多来的最大利润。</blockquote></p><p> Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>埃克森美孚股价在盘前交易中上涨近1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p><p><blockquote>石油生产商正在利用上季度原油价格翻倍的机会削减债务并增加股东派息，而不是增加支出来提高产量。</blockquote></p><p> Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p><p><blockquote>由于 COVID-19 大流行大幅削减需求，去年实施的大幅成本削减措施仍然有效，价格上涨推高了利润。</blockquote></p><p> Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p><p><blockquote>石油和天然气生产在本季度领先，营业利润为 31.9 亿美元。本季度产量下降 2%，至每天 360 万桶油当量。</blockquote></p><p> The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p><p><blockquote>该公司第二季度净利润为 46.9 亿美元，即每股 1.10 美元，而去年同期亏损 10.8 亿美元，即每股 26 美分，其中包括与扭转库存减记相关的收益。如果没有库存变化，损失将达到30亿美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exxon posts highest profit in more than a year<blockquote>埃克森美孚公布一年多来最高利润</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExxon posts highest profit in more than a year<blockquote>埃克森美孚公布一年多来最高利润</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-30 19:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p><p><blockquote>埃克森美孚周五公布了第一份季度业绩，此前董事会就其方向展开了一场有争议的斗争，由于石油、天然气和化学品需求反弹，埃克森美孚实现了一年多来的最大利润。</blockquote></p><p> Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>埃克森美孚股价在盘前交易中上涨近1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p><p><blockquote>石油生产商正在利用上季度原油价格翻倍的机会削减债务并增加股东派息，而不是增加支出来提高产量。</blockquote></p><p> Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p><p><blockquote>由于 COVID-19 大流行大幅削减需求，去年实施的大幅成本削减措施仍然有效，价格上涨推高了利润。</blockquote></p><p> Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p><p><blockquote>石油和天然气生产在本季度领先，营业利润为 31.9 亿美元。本季度产量下降 2%，至每天 360 万桶油当量。</blockquote></p><p> The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p><p><blockquote>该公司第二季度净利润为 46.9 亿美元，即每股 1.10 美元，而去年同期亏损 10.8 亿美元，即每股 26 美分，其中包括与扭转库存减记相关的收益。如果没有库存变化，损失将达到30亿美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155158989","content_text":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.\nExxon Mobil shares rose nearly 1% in premarket trading.\n\nOil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.\nDeep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.\nOil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.\nThe company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.","news_type":1,"symbols_score_info":{"XOM":0.9}},"isVote":1,"tweetType":1,"viewCount":2298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145269204,"gmtCreate":1626225863108,"gmtModify":1631885218880,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","listText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","text":"$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound","images":[{"img":"https://static.tigerbbs.com/348777b05f0b9f48562e326dd94278ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/145269204","isVote":1,"tweetType":1,"viewCount":1233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125760127,"gmtCreate":1624694613169,"gmtModify":1631891361256,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"Yes APPLE is definitely a better buy😉","listText":"Yes APPLE is definitely a better buy😉","text":"Yes APPLE is definitely a better buy😉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125760127","repostId":"1108941456","repostType":4,"isVote":1,"tweetType":1,"viewCount":669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125222641,"gmtCreate":1624676342883,"gmtModify":1631893057831,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"It is kinda&nbsp;high now to buy in ~","listText":"It is kinda&nbsp;high now to buy in ~","text":"It is kinda high now to buy in ~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/125222641","repostId":"1100072036","repostType":4,"isVote":1,"tweetType":1,"viewCount":513,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":856808141,"gmtCreate":1635166163293,"gmtModify":1635166163416,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856808141","repostId":"1137044759","repostType":4,"isVote":1,"tweetType":1,"viewCount":3112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}